The Role of Glycosylation in Therapeutic Antibodies

2011 ◽  
pp. 251-292 ◽  
Author(s):  
Maureen Spearman ◽  
Ben Dionne ◽  
Michael Butler
Keyword(s):  
Therapeutic Antibodies

Role of convalescent plasma therapy in new Coronavirus disease (nCOVID-19): A review

2020 ◽  
Vol 11 (SPL1) ◽  
pp. 546-549
Author(s):  
Shweta Dadarao Parwe ◽  
Milind Abhimanyu Nisargandha ◽  
Rishikesh Thakre
Keyword(s):  
Clinical Trial ◽  
Immune Responses ◽  
Indian Population ◽  
Preventive Treatment ◽  
The Body ◽  
Therapeutic Antibodies ◽  
Plasma Therapy ◽  
Host Immune Responses ◽  
Transparent Liquid

Hitherto, there is no proper line of treatment for the new (nCOVID19). The development of unique antiviral drugs has taken precedence. Therapeutic antibodies () will be a significantly beneficial agent against nCOVID-19. Here the host immune responses to new discussed in this review provide strategy and further treatment and understanding of clinical interventions against nCOVID-19. Plasma therapy uses the antibodies found in the blood of people recovering (or convalesced) from an infection to treat infected patients. When an infection occurs, the body begins producing proteins specially made to kill the germ, called antibodies. Those antibodies coat specifically plasma in the blood of survivors, the yellow transparent liquid blood portion for months or even years. research assesses plasma use from Convalescent patients of infected with nCOVID-19 as a possible preventive treatment. But it is not yet recommended as a line of treatment, and it is used as a clinical trial in the new in Indian population.

The growing role of structural mass spectrometry in the discovery and development of therapeutic antibodies

The Analyst ◽  
2018 ◽  
Vol 143 (11) ◽  
pp. 2459-2468 ◽  
Author(s):  
Yuwei Tian ◽  
Brandon T. Ruotolo
Keyword(s):  
Mass Spectrometry ◽  
State Of The Art ◽  
Therapeutic Antibodies ◽  
Critical Importance ◽  
Current State ◽  
Measurement Science ◽  
Structural Mass Spectrometry ◽  
Structural Mass

The comprehensive structural characterization of therapeutic antibodies is of critical importance for the successful discovery and development of such biopharmaceuticals, yet poses many challenges to modern measurement science. Here, we review the current state-of-the-art mass spectrometry technologies focusing on the characterization of antibody-based therapeutics.

Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies

Methods ◽  
2014 ◽  
Vol 65 (1) ◽  
pp. 95-104 ◽  
Author(s):  
Brian D. Harms ◽  
Jeffrey D. Kearns ◽  
Sergio Iadevaia ◽  
Alexey A. Lugovskoy
Keyword(s):  
Therapeutic Antibodies

The Role of Biosimilars in Patient Access to Therapeutic Antibodies for Immune Mediated Inflammatory Diseases

2018 ◽  
Vol 23 (44) ◽  
pp. 6779-6783 ◽  
Author(s):  
Mary Ann Chapman ◽  
David Charles ◽  
Arturo Loaiza-Bonilla
Keyword(s):  
Inflammatory Diseases ◽  
Therapeutic Antibodies ◽  
Patient Access ◽  
Immune Mediated

Role of Fc–FcγR interactions in the antitumor activity of therapeutic antibodies

2017 ◽  
Vol 95 (4) ◽  
pp. 340-346 ◽  
Author(s):  
Bryan C Barnhart ◽  
Michael Quigley
Keyword(s):  
Antitumor Activity ◽  
Therapeutic Antibodies

scholarly journals PD-L1 Promotes Self-Renewal and Tumorigenicity of Malignant Melanoma Initiating Cells

2017 ◽  
Vol 2017 ◽  
pp. 1-8 ◽  
Author(s):  
Fang Zheng ◽  
Jianzhong Dang ◽  
Hui Zha ◽  
Bingyu Zhang ◽  
Ming Lin ◽  
...  
Keyword(s):  
Flow Cytometry ◽  
Malignant Melanoma ◽  
Tumor Growth ◽  
Melanoma Cell ◽  
Therapeutic Antibodies ◽  
Self Renewal ◽  
Regulatory Effects ◽  
Melanoma Cell Lines

Recent studies have indicated that therapeutic antibodies targeting PD-L1 show remarkable efficacy in clinical trials in multiple tumors and that a melanoma cell-intrinsic PD-1: PD-L1 axis promotes tumor growth. However, few studies have shown tumor-intrinsic PD-L1 effects in malignant melanoma initiating cells (MMICs). Here, we aim to determine the possible regulatory effects of PD-L1 on MMICs. The ALDEFLUOR kit was used to identify ALDH+ MMICs. Flow cytometry was used to examine the expression of PD-L1 on ALDH+ MMICs. To determine the role of PD-L1 in MMICs self-renewal, we cultured melanoma cells with anti-PD-L1 and measured tumorsphere formation and apoptosis. In addition, the effects of anti-PD-L1 on tumorigenicity and residual ALDH+ MMICs in tumors were evaluated in vivo. We demonstrated that melanoma cell-intrinsic PD-L1 was expressed in ALDH+ MMICs. Blocking PD-L1 in melanoma cell lines impaired tumorsphere formation and induced the apoptosis of sphere cells. In addition, blocking PD-L1 inhibited tumor growth in vivo. We observed residual ALDH+ MMICs within the tumor. The results showed that blocking PD-L1 also significantly decreased the residual ALDH+ MMICs in the tumors. In conclusion, these results suggest a new mechanism underlying melanoma progression and PD-L1-targeted therapy, which is distinct from the immunomodulatory actions of PD-L1.

The Expanding Role of Therapeutic Antibodies

2014 ◽  
Vol 34 (3) ◽  
pp. 202-264 ◽  
Author(s):  
Simonetta Salemi ◽  
Milica Markovic ◽  
Gabriella Martini ◽  
Raffaele D'Amelio
Keyword(s):  
Therapeutic Antibodies

The role of Fc-receptors in the uptake and transport of therapeutic antibodies in the retinal pigment epithelium

2016 ◽  
Vol 145 ◽  
pp. 187-205 ◽  
Author(s):  
Michaela Dithmer ◽  
Kirsten Hattermann ◽  
Prasti Pomarius ◽  
Shereen Hassan Aboul Naga ◽  
Tim Meyer ◽  
...  
Keyword(s):  
Retinal Pigment Epithelium ◽  
Pigment Epithelium ◽  
Retinal Pigment ◽  
Fc Receptors ◽  
Therapeutic Antibodies ◽  
Uptake And Transport

scholarly journals Role of CD146 (MCAM) in Physiological and Pathological Angiogenesis—Contribution of New Antibodies for Therapy

Biomedicines ◽  
2020 ◽  
Vol 8 (12) ◽  
pp. 633
Author(s):  
Ahmad Joshkon ◽  
Xavier Heim ◽  
Cléa Dubrou ◽  
Richard Bachelier ◽  
Wael Traboulsi ◽  
...  
Keyword(s):  
Cell Adhesion Molecules ◽  
Interstitial Fluid ◽  
Immunoglobulin Superfamily ◽  
Soluble Form ◽  
Biological Processes ◽  
Therapeutic Antibodies ◽  
Pathological Angiogenesis ◽  
Growing Body ◽  
Soluble Cd146

The fundamental role of cell adhesion molecules in mediating various biological processes as angiogenesis has been well-documented. CD146, an adhesion molecule of the immunoglobulin superfamily, and its soluble form, constitute major players in both physiological and pathological angiogenesis. A growing body of evidence shows soluble CD146 to be significantly elevated in the serum or interstitial fluid of patients with pathologies related to deregulated angiogenesis, as autoimmune diseases, obstetric and ocular pathologies, and cancers. To block the undesirable effects of this molecule, therapeutic antibodies have been developed. Herein, we review the multifaceted functions of CD146 in physiological and pathological angiogenesis and summarize the interest of using monoclonal antibodies for therapeutic purposes.

Sign in / Sign up

Export Citation Format

Share Document